BR9714434A - Formulações de interferon liquidas estáveis - Google Patents

Formulações de interferon liquidas estáveis

Info

Publication number
BR9714434A
BR9714434A BR9714434-7A BR9714434A BR9714434A BR 9714434 A BR9714434 A BR 9714434A BR 9714434 A BR9714434 A BR 9714434A BR 9714434 A BR9714434 A BR 9714434A
Authority
BR
Brazil
Prior art keywords
liquid
interferon
compositions
stable liquid
beta
Prior art date
Application number
BR9714434-7A
Other languages
English (en)
Inventor
Mary D Dibiasi
Mark Staples
Wen-Li Chung
Erick Scharin
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21875893&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9714434(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of BR9714434A publication Critical patent/BR9714434A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Patente de Invenção: <B>"FORMULAçõES DE INTERFERON LìQUIDAS ESTáVEIS"<D>. São descritas composições de interferon líquidas tendo um pH entre 4,0 e 7,2. As composições compreendem interferon-beta e um agente de estabilização entre cerca de 0,3% e 5% em peso que é um aminoácido selecionado do grupo que consiste de aminoácidos ácidos, arginina e glicina. Se necessário, sal é adicionado para prover concentração iónica suficiente. A composição líquida não foi anteriormente liofilizada ou anteriormente cavitada. O líquido está de preferência contido dentro de um recipiente tendo pelo menos uma superfície em contato com o líquido que é revestido com um material inerte à adsorção de interferon-beta. São descritos um kit para a administração parenteral de uma formulação de interferon líquida e um método para a estabilização de composições de interferon líquidas.
BR9714434-7A 1996-12-24 1997-12-23 Formulações de interferon liquidas estáveis BR9714434A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3435396P 1996-12-24 1996-12-24
PCT/US1997/023817 WO1998028007A1 (en) 1996-12-24 1997-12-23 Stable liquid interferon formulations

Publications (1)

Publication Number Publication Date
BR9714434A true BR9714434A (pt) 2000-05-02

Family

ID=21875893

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9714434-7A BR9714434A (pt) 1996-12-24 1997-12-23 Formulações de interferon liquidas estáveis

Country Status (28)

Country Link
EP (1) EP0948358B2 (pt)
JP (5) JP4878664B2 (pt)
KR (2) KR101042660B1 (pt)
CN (2) CN1222315C (pt)
AT (1) ATE270899T1 (pt)
AU (1) AU738362B2 (pt)
BG (2) BG65171B1 (pt)
BR (1) BR9714434A (pt)
CA (1) CA2275890C (pt)
CZ (1) CZ300636B6 (pt)
DE (1) DE69729880T3 (pt)
DK (1) DK0948358T4 (pt)
EA (1) EA002754B1 (pt)
EE (2) EE04266B1 (pt)
ES (1) ES2224290T5 (pt)
HK (2) HK1025040A1 (pt)
HU (1) HU224222B1 (pt)
IL (1) IL130524A (pt)
IS (1) IS2070B (pt)
MX (1) MX337876B (pt)
NO (1) NO327844B1 (pt)
NZ (2) NZ336548A (pt)
PL (1) PL193447B1 (pt)
PT (1) PT948358E (pt)
SI (1) SI0948358T2 (pt)
SK (1) SK284989B6 (pt)
TR (1) TR199901968T2 (pt)
WO (1) WO1998028007A1 (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
HU224222B1 (hu) * 1996-12-24 2005-06-28 Biogen Inc. Stabil folyékony interferon-készítményformák és eljárás interferon stabilizálására
CA2304808C (en) 1997-09-23 2011-03-22 Michael Tschope Liquid interferon-.beta. formulations
CA2375779A1 (en) * 1999-05-31 2000-12-07 Mitsubishi Chemical Corporation Lyophilized hgf preparation
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
JP4340540B2 (ja) * 2002-01-18 2009-10-07 旭化成ファーマ株式会社 可溶性トロンボモジュリン高濃度含有製剤
AU2003240438A1 (en) 2002-06-21 2004-01-06 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
EP1628677B1 (en) 2003-05-23 2010-01-13 Novo Nordisk Health Care AG Protein stabilization in solution
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
KR101293503B1 (ko) 2003-08-14 2013-08-07 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
WO2005051456A2 (en) * 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
PL2298287T3 (pl) 2003-12-19 2019-02-28 Novo Nordisk Health Care Ag Stabilizowane kompozycje polipeptydów czynnika VII
UA93349C2 (ru) * 2004-06-01 2011-02-10 Эйрэс Трейдинг C.A. Способ стабилизации мономерного белка интерферона
WO2006022301A1 (ja) * 2004-08-24 2006-03-02 Daiichi Asubio Pharma Co., Ltd. 生理活性ペプチド液状製剤
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
PL1809662T3 (pl) * 2004-11-10 2009-07-31 Novartis Vaccines & Diagnostics Inc Dezamidowany interferon-beta
BRPI0606658B8 (pt) 2005-01-12 2021-05-25 Biogen Idec Inc método para armazenar e distribuir interferon-beta, e dispositivo
WO2006079019A2 (en) * 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
ATE501248T1 (de) 2005-07-02 2011-03-15 Arecor Ltd Stabile wässrige systeme mit proteinen
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN103951667A (zh) 2006-05-04 2014-07-30 勃林格殷格翰国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
ES2638977T3 (es) * 2007-12-04 2017-10-24 Biogen Chesapeake Llc Formulaciones y procedimientos mejorados para liofilización y liofilizados obtenidos por los mismos
EP2234645B1 (en) 2007-12-20 2012-05-02 Merck Serono S.A. Peg-interferon-beta formulations
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
CA2726824A1 (en) 2008-05-01 2009-11-05 Arecor Limited Protein formulation
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
DE102008051574A1 (de) 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
JP6078344B2 (ja) 2010-02-04 2017-02-08 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 免疫グロブリン製剤
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
DE102010011430A1 (de) * 2010-03-15 2011-09-15 Kurt Koch Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
EA033415B1 (ru) 2010-05-05 2019-10-31 Boehringer Ingelheim Int Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2
BR112012032579B1 (pt) 2010-06-24 2021-05-11 Boehringer Ingelheim International Gmbh uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9452216B2 (en) 2010-12-09 2016-09-27 Maruishi Pharmaceutical Co., Ltd. Agent for stabilizing acetaminophen
US9198955B2 (en) * 2011-03-15 2015-12-01 Biogen Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
NZ618698A (en) 2011-07-15 2015-08-28 Boehringer Ingelheim Int Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130280346A1 (en) * 2012-04-19 2013-10-24 C. R. Bard, Inc. Infusates with Enhanced pH Stability Under Ethylene Oxide Sterilization
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ITMI20120913A1 (it) 2012-05-28 2013-11-29 Nicoletta Maxia Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
CN103143000B (zh) * 2013-03-07 2014-11-05 安徽安科生物工程（集团）股份有限公司 一种重组人干扰素α2b制剂
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
JP2014208669A (ja) * 2014-06-17 2014-11-06 株式会社スリー・ディー・マトリックス タンパク質の凝集抑制剤
MX2018015089A (es) 2016-06-10 2019-05-13 Boehringer Ingelheim Int Combinacion de linagliptina y metformina.
KR101943160B1 (ko) 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
MX2020001855A (es) 2017-08-22 2020-08-13 Biogen Ma Inc Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
KR20210009982A (ko) * 2019-07-18 2021-01-27 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
CN110714051B (zh) * 2019-11-20 2023-04-07 迈克生物股份有限公司 蛋白c活性测定试剂盒
AU2021264372A1 (en) * 2020-04-29 2022-12-15 Abion Inc. Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant
CN114177273B (zh) * 2021-11-29 2024-05-28 苏州人本药业有限公司 一种含有神经毒素的液体制剂及其制备方法
US20230210857A1 (en) * 2021-12-27 2023-07-06 Enalare Therapeutics Inc. Respiratory stimulant parenteral formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57175125A (en) * 1981-04-20 1982-10-28 Wakunaga Yakuhin Kk Preparation of beta-interferon
DE3262575D1 (en) * 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
JPS63196268A (ja) * 1987-02-10 1988-08-15 Kanegafuchi Chem Ind Co Ltd 無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
JPH02124832A (ja) * 1988-07-08 1990-05-14 Toray Ind Inc インターヘェロンβ組成物
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon
TW249202B (pt) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
CA2185353A1 (en) * 1994-04-08 1995-10-19 David A. Hafler Treatment of autoimmune disease using oral tolerization and/or type i interferon
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
HU224222B1 (hu) * 1996-12-24 2005-06-28 Biogen Inc. Stabil folyékony interferon-készítményformák és eljárás interferon stabilizálására

Also Published As

Publication number Publication date
DK0948358T4 (da) 2012-03-19
JP2007204501A (ja) 2007-08-16
SI0948358T2 (sl) 2012-03-30
EA002754B1 (ru) 2002-08-29
CZ228299A3 (cs) 1999-12-15
JP2014098029A (ja) 2014-05-29
IL130524A (en) 2005-08-31
KR20000069664A (ko) 2000-11-25
JP5851695B2 (ja) 2016-02-03
DE69729880D1 (de) 2004-08-19
DE69729880T2 (de) 2005-07-07
NO993121D0 (no) 1999-06-23
KR101042660B1 (ko) 2011-06-20
JP2012006979A (ja) 2012-01-12
AU5619198A (en) 1998-07-17
IL130524A0 (en) 2000-06-01
IS5087A (is) 1999-06-21
NZ336548A (en) 2001-09-28
TR199901968T2 (xx) 1999-12-21
CA2275890C (en) 2011-11-01
PL334365A1 (en) 2000-02-28
CN1245434A (zh) 2000-02-23
PL193447B1 (pl) 2007-02-28
WO1998028007A1 (en) 1998-07-02
EE04266B1 (et) 2004-04-15
DE69729880T3 (de) 2012-05-10
ES2224290T3 (es) 2005-03-01
HK1092048A1 (en) 2007-02-02
JP4878664B2 (ja) 2012-02-15
EE200300127A (et) 2003-06-16
IS2070B (is) 2005-12-15
JP2001519770A (ja) 2001-10-23
EE9900313A (et) 2000-04-17
ES2224290T5 (es) 2012-03-12
SK85899A3 (en) 2000-01-18
DK0948358T3 (da) 2004-11-08
KR20070052363A (ko) 2007-05-21
BG109523A (en) 2007-05-31
CA2275890A1 (en) 1998-07-02
CZ300636B6 (cs) 2009-07-08
CN1733296B (zh) 2010-05-26
NO993121L (no) 1999-08-24
HUP0000829A2 (en) 2000-07-28
HK1025040A1 (en) 2000-11-03
CN1222315C (zh) 2005-10-12
NO327844B1 (no) 2009-10-05
SK284989B6 (sk) 2006-04-06
PT948358E (pt) 2004-10-29
SI0948358T1 (en) 2005-04-30
CN1733296A (zh) 2006-02-15
NZ512792A (en) 2002-11-26
BG65418B1 (bg) 2008-07-31
EP0948358B1 (en) 2004-07-14
BG65171B1 (bg) 2007-05-31
HU224222B1 (hu) 2005-06-28
EP0948358B2 (en) 2011-11-23
JP2011068694A (ja) 2011-04-07
HUP0000829A3 (en) 2002-01-28
EE04223B1 (et) 2004-02-16
AU738362B2 (en) 2001-09-13
MX337876B (es) 2016-03-22
EA199900597A1 (ru) 2000-02-28
BG103594A (en) 2000-04-28
ATE270899T1 (de) 2004-07-15
EP0948358A1 (en) 1999-10-13

Similar Documents

Publication Publication Date Title
BR9714434A (pt) Formulações de interferon liquidas estáveis
BR0014486A (pt) Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
DK0831773T3 (da) Suspenderede peptid/proteinformuleringer
BR9913343A (pt) Formulações de caseìna para a distribuição de constituintes bioativos
BR0215216A (pt) Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
BR9909329A (pt) Método para estabilizar composições farmacêuticas pelo uso especial de um antioxidante
CA2113995A1 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
DE68920931D1 (de) Rekombinanter natürlicher Killerzellen-Aktivator.
KR950024769A (ko) 고농도 tcf 제제
ES2075107T3 (es) Composiciones que contienen ibuprofeno y s(+)-ibuprofeno, y procedimiento para su preparacion.
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
KR910005884A (ko) 단백질 수용액
EP0063328A3 (en) Compositions containing secretin and method for preventing the adsorption of secretin
AR008764A1 (es) Sales hidratadas de n,n&#39;-diacetilcistina, proceso para su preparacion, y composiciones terapeuticas que comprenden a dichas sales como ingredienteactivo.
KR950023648A (ko) 생물학적 활성을 나타내는 폴리펩티드
KR920009847A (ko) 트롬빈 결합성 물질 및 그의 제조방법

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BIOGEN IDEC MA INC. (US)

Free format text: ALTERADO DE: BIOGEN IDEC MA, INC.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, OPINO PELO INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM O ART. 13 DA LPI).

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BIOGEN MA INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]